Alpha polyglutamated aminopterin and uses thereof
AssigneeL.E.A.F. Holdings Group LLC
InventorsClet Niyikiza, Victor Mandla Moyo
Life of this patent
Estimating the term…
Abstract
The disclosure relates generally to alpha polyglutamated aminopterin, formulations containing liposomes filled with alpha polyglutamated aminopterin, methods of making the alpha polyglutamated aminopterin and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated aminopterin and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).
Claims20
A liposomal composition comprising an alpha polyglutamated aminopterin encapsulated by a liposome, wherein the alpha polyglutamated aminopterin contains 4-6, 4, 5, or more than 5 glutamyl groups having an alpha carboxyl group linkage, wherein the liposome is pegylated, wherein the liposome does not contain a targeting moiety having specific affinity for a surface antigen on a target cell,
- wherein the liposome does not contain a cell penetrating peptide and does not contain a mitochondria penetrating peptide,
- wherein the liposome has a zeta potential that is less than or equal to zero, between 0 to −150 mV, or between −30 to −50 mV, and
- wherein the liposome is capable of delivering the alpha polyglutamated aminopterin directly into a cell.
Dependencies are inferred from the claim text.